Literature DB >> 19221054

Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T.

Takeshi Yokoo1, Mark Bydder, Gavin Hamilton, Michael S Middleton, Anthony C Gamst, Tanya Wolfson, Tarek Hassanein, Heather M Patton, Joel E Lavine, Jeffrey B Schwimmer, Claude B Sirlin.   

Abstract

PURPOSE: To assess the accuracy of four fat quantification methods at low-flip-angle multiecho gradient-recalled-echo (GRE) magnetic resonance (MR) imaging in nonalcoholic fatty liver disease (NAFLD) by using MR spectroscopy as the reference standard.
MATERIALS AND METHODS: In this institutional review board-approved, HIPAA-compliant prospective study, 110 subjects (29 with biopsy-confirmed NAFLD, 50 overweight and at risk for NAFLD, and 31 healthy volunteers) (mean age, 32.6 years +/- 15.6 [standard deviation]; range, 8-66 years) gave informed consent and underwent MR spectroscopy and GRE MR imaging of the liver. Spectroscopy involved a long repetition time (to suppress T1 effects) and multiple echo times (to estimate T2 effects); the reference fat fraction (FF) was calculated from T2-corrected fat and water spectral peak areas. Imaging involved a low flip angle (to suppress T1 effects) and multiple echo times (to estimate T2* effects); imaging FF was calculated by using four analysis methods of progressive complexity: dual echo, triple echo, multiecho, and multiinterference. All methods except dual echo corrected for T2* effects. The multiinterference method corrected for multiple spectral interference effects of fat. For each method, the accuracy for diagnosis of fatty liver, as defined with a spectroscopic threshold, was assessed by estimating sensitivity and specificity; fat-grading accuracy was assessed by comparing imaging and spectroscopic FF values by using linear regression.
RESULTS: Dual-echo, triple-echo, multiecho, and multiinterference methods had a sensitivity of 0.817, 0.967, 0.950, and 0.983 and a specificity of 1.000, 0.880, 1.000, and 0.880, respectively. On the basis of regression slope and intercept, the multiinterference (slope, 0.98; intercept, 0.91%) method had high fat-grading accuracy without statistically significant error (P > .05). Dual-echo (slope, 0.98; intercept, -2.90%), triple-echo (slope, 0.94; intercept, 1.42%), and multiecho (slope, 0.85; intercept, -0.15%) methods had statistically significant error (P < .05).
CONCLUSION: Relaxation- and interference-corrected fat quantification at low-flip-angle multiecho GRE MR imaging provides high diagnostic and fat-grading accuracy in NAFLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221054      PMCID: PMC2663579          DOI: 10.1148/radiol.2511080666

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  50 in total

1.  Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals.

Authors:  A Naressi; C Couturier; I Castang; R de Beer; D Graveron-Demilly
Journal:  Comput Biol Med       Date:  2001-07       Impact factor: 4.589

Review 2.  Treatment of nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  Ann Hepatol       Date:  2002 Jan-Mar       Impact factor: 2.400

3.  Relaxation effects in the quantification of fat using gradient echo imaging.

Authors:  Mark Bydder; Takeshi Yokoo; Gavin Hamilton; Michael S Middleton; Alyssa D Chavez; Jeffrey B Schwimmer; Joel E Lavine; Claude B Sirlin
Journal:  Magn Reson Imaging       Date:  2008-02-21       Impact factor: 2.546

4.  Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise.

Authors:  Chia-Ying Liu; Charles A McKenzie; Huanzhou Yu; Jean H Brittain; Scott B Reeder
Journal:  Magn Reson Med       Date:  2007-08       Impact factor: 4.668

Review 5.  Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: a review.

Authors:  Frank Fischbach; Harald Bruhn
Journal:  Liver Int       Date:  2008-03       Impact factor: 5.828

6.  Liver biopsy:complications and risk factors.

Authors:  Pornpen Thampanitchawong; Teerha Piratvisuth
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

7.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge

Authors: 
Journal:  J Magn Reson       Date:  1997-11       Impact factor: 2.229

8.  Non-invasive quantification of hepatic fat fraction by fast 1.0, 1.5 and 3.0 T MR imaging.

Authors:  Sebastian Schuchmann; Christiane Weigel; Lothar Albrecht; Michael Kirsch; Arne Lemke; Gerd Lorenz; Rolf Warzok; Norbert Hosten
Journal:  Eur J Radiol       Date:  2007-01-30       Impact factor: 3.528

9.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

10.  Effects of intravenous gadolinium administration and flip angle on the assessment of liver fat signal fraction with opposed-phase and in-phase imaging.

Authors:  Takeshi Yokoo; Julie M Collins; Robert F Hanna; Mark Bydder; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2008-07       Impact factor: 4.813

View more
  151 in total

Review 1.  Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.

Authors:  Scott B Reeder; Irene Cruite; Gavin Hamilton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2011-09-16       Impact factor: 4.813

Review 2.  Quantification of liver fat with magnetic resonance imaging.

Authors:  Scott B Reeder; Claude B Sirlin
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-08       Impact factor: 2.266

3.  Liver steatosis: concordance of MR imaging and MR spectroscopic data with histologic grade.

Authors:  Susan M Noworolski; Maggie M Lam; Raphael B Merriman; Linda Ferrell; Aliya Qayyum
Journal:  Radiology       Date:  2012-07       Impact factor: 11.105

4.  In vivo characterization of the liver fat ¹H MR spectrum.

Authors:  Gavin Hamilton; Takeshi Yokoo; Mark Bydder; Irene Cruite; Michael E Schroeder; Claude B Sirlin; Michael S Middleton
Journal:  NMR Biomed       Date:  2010-12-12       Impact factor: 4.044

5.  Free-breathing liver fat and R 2 quantification using motion-corrected averaging based on a nonlocal means algorithm.

Authors:  Huiwen Luo; Ante Zhu; Curtis N Wiens; Jitka Starekova; Ann Shimakawa; Scott B Reeder; Kevin M Johnson; Diego Hernando
Journal:  Magn Reson Med       Date:  2020-08-01       Impact factor: 4.668

6.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.

Authors:  An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Radiology       Date:  2013-02-04       Impact factor: 11.105

Review 7.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

8.  MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends.

Authors:  Guido Ligabue; Giulia Besutti; Riccardo Scaglioni; Chiara Stentarelli; Giovanni Guaraldi
Journal:  Quant Imaging Med Surg       Date:  2013-08

9.  Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women.

Authors:  Jennifer L Rehm; Peter M Wolfgram; Diego Hernando; Jens C Eickhoff; David B Allen; Scott B Reeder
Journal:  Eur Radiol       Date:  2015-04-28       Impact factor: 5.315

Review 10.  Evidence and recommendations for imaging liver fat in children, based on systematic review.

Authors:  Hannah I Awai; Kimberly P Newton; Claude B Sirlin; Cynthia Behling; Jeffrey B Schwimmer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-30       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.